Hutchison MediPharma | Press Releases

14-Jun-2019

HMP Announces that Surufatinib Phase III SANET-ep Study Has Met its Primary Endpoint at Interim Analysis in Advanced Non-Pancreatic Neuroendocrine Tumors in China and Will Stop Early

29-Mar-2019

HMP Initiates a Phase IIb/III Trial of Surufatinib in Patients with Unresectable or Metastatic Biliary Tract Cancer in China

28-Mar-2019

HMP Highlights Oral Presentations on Savolitinib Lung Cancer Programs at AACR Annual Meeting

12-Feb-2019

HMP Highlights Preliminary Phase II Savolitinib / Imfinzi® Combination Data in Advanced Papillary Renal Cell Carcinoma at 2019 ASCO Genitourinary Cancers Symposium

20-Dec-2018

HMP Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company

20-Dec-2018

HMP Announces Progress in Savolitinib Lung Cancer Program and Update on Kidney Cancer Strategy

29-Nov-2018

HMP Enters into Multiple Collaborations to Evaluate Combinations of Surufatinib and Fruquintinib with PD-1 Checkpoint Inhibitors

26-Nov-2018

HMP Announces First Commercial Launch of Fruquintinib Capsules (Elunate®)

16-Nov-2018

HMP Announces Phase III FALUCA Trial Results for Fruquintinib in Third-Line, Advanced Non-Small Cell Lung Cancer in China

05-Sep-2018

HMP Announces the Approval of Fruquintinib Capsules for Previously Treated Colorectal Cancer in China